Search Menu
Photonics Media Photonics Buyers' Guide Photonics EDU Photonics Spectra BioPhotonics EuroPhotonics Industrial Photonics Photonics Showcase Photonics ProdSpec Photonics Handbook
More News
Email Facebook Twitter Google+ LinkedIn Comments

FluoroPharma Inc.

Sep 2008
FluoroPharma Inc. of Boston, a developer of molecular imaging agents for the PET market, has announced successful Phase I safety results for BFPET, a fluorine-18-labeled tracer for myocardial perfusion imaging. The imaging agent analyzes blood flow in the heart and assesses coronary artery disease in patients.

BiophotonicsenergyFluoroPharma Inc.molecular imagingmyocardial perfusion imagingNews & Features

Terms & Conditions Privacy Policy About Us Contact Us
back to top
Facebook Twitter Instagram LinkedIn YouTube RSS
©2019 Photonics Media, 100 West St., Pittsfield, MA, 01201 USA,

Photonics Media, Laurin Publishing
x Subscribe to BioPhotonics magazine - FREE!
We use cookies to improve user experience and analyze our website traffic as stated in our Privacy Policy. By using this website, you agree to the use of cookies unless you have disabled them.